Data highlight benefits of TYSABRI® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and.

source https://finance.yahoo.com/news/research-demonstrate-biogen-continued-commitment-090000171.html?.tsrc=rss